TAUNS Laboratories, Inc. (197A) Stock Price

Towns is a company that manufactures and sells in vitro diagnostic antigen test kits for infectious diseases. Its flagship products are rapid test kits using immunochromatographic methods that require no special equipment. The company offers a product lineup centered on tests that deliver results quickly in the field, with an emphasis on quality and ease of use.

The company's primary customers include hospitals and private clinics through pharmaceutical wholesalers, as well as international organizations such as the WHO, research institutions, and bioventures. While sales are primarily domestic, the company also operates internationally. Revenue is driven mainly by test kit sales, with adoption driven by kit convenience and the standardization of specimen extraction solutions.

The business operates as a single segment focused on in vitro diagnostic pharmaceuticals. The product line includes influenza, COVID-19 (nasopharyngeal and saliva), simultaneous dual testing kits, as well as adenovirus, RSV, mycoplasma, and norovirus tests. Each kit features distinct characteristics such as detection time, specimen type, and high-visibility black lines. The company's competitive differentiation lies in design that reduces the burden of specimen collection frequency and operational steps.

The company operates under the mission "Diagnostic technology for peace of mind every day." It aims to drive business growth centered on diagnostic technology and data. While specific numerical targets are not disclosed, the medium-term management plan emphasizes key performance indicators including revenue, operating profit, net income, operating margin, EBITDA, and ROE. The company's strategy focuses on reducing dependence on specific products and strengthening its earnings foundation through product line diversification, international expansion, and establishment of new manufacturing facilities. Currently, COVID-19-related products represent a significant portion of sales; however, the company aims to achieve stable long-term growth through next-generation technology deployment and market development.

R&D and capital investment priorities include development of next-generation testing platforms alongside existing immunochromatography methods, enhanced antibody development capabilities, and diagnostic technologies for chronic disease and preventive care. The company's differentiating factor is D-IA (Digital Immunoassay), currently in development, which uses chip-based reagents to deliver high-precision testing on compact devices, capable of processing up to 20 samples simultaneously and performing multiple tests at once. The company is also expanding its portfolio of high-value products for clinic and home use through immune profiling and multiomics analysis including genomics, as well as developing chronic disease products such as simplified urinalysis and "Accuread Zinc."

For domestic expansion, the company is increasing sales personnel, strengthening relationships with key distributors, and expanding distribution channels through co-marketing with pharmaceutical companies. Internationally, the company is expanding into new regions by reinforcing existing distributor networks while developing cost-optimized products for overseas markets and building regulatory and local expert relationships. Additionally, the company plans to establish new manufacturing facilities to expand existing production lines and add new product-capable lines. Factory automation will improve labor efficiency and quality consistency, while transitioning from single to dual-site operations will enhance business continuity (BCP).

Technology innovation efforts span both hardware and software. For D-IA, the company aims to achieve high-sensitivity detection and quantification through single-particle counting of gold colloid particles, enabling faster and multi-parameter testing. Simultaneously, the company is investing in new diagnostic areas such as immune profiling and microbiome analysis, while upgrading information infrastructure and core systems to leverage testing data. For human capital, the company is strengthening recruitment of specialized talent and advanced technology education including AI, and will build necessary technological foundations for its ten-year business vision through intellectual property investment and technology and capital partnerships.